New hope for genital eczema: tralokinumab trial launches

NCT ID NCT07444801

Recruiting now Disease control Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

First seen Mar 19, 2026 · Last updated Apr 25, 2026 · Updated 7 times

Summary

This study tests the drug tralokinumab in 30 adults with moderate-to-severe atopic dermatitis (eczema) that affects the genital area. The goal is to see if the treatment reduces itching and skin symptoms over 52 weeks. Participants receive the drug as part of their regular care, and researchers track improvements using special scoring tools and skin imaging.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CCIM, Institut für Entzündungsmedizin UKSH Lübeck
RECRUITING

Lübeck, Schleswig-Holstein, 23538, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Department of Dermatology of the University Hospital Augsburg
RECRUITING

Augsburg, München, 86156, Germany

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ATOPIC DERMATITIS (MODERATE-TO-SEVERE) INVOLVING THE GENITAL REGION